{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:02Z","timestamp":1786982762445,"version":"build-2736575974"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40263-025-01227-y","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:58:56Z","timestamp":1761112736000},"page":"1355-1364","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Viloxazine Extended-Release: A Review in Attention-Deficit\/Hyperactivity Disorder in Adults"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1028-8594","authenticated-orcid":false,"given":"Yahiya Y.","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"1227_CR1","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, Text Revision (DSM-5-TR\u2122): American Psychiatric Publishing; 2022."},{"issue":"6","key":"1227_CR2","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/jcpp.12620","volume":"58","author":"MH Sibley","year":"2017","unstructured":"Sibley MH, Swanson JM, Arnold LE, et al. Defining ADHD symptom persistence in adulthood: optimizing sensitivity and specificity. J Child Psychol Psychiatry. 2017;58(6):655\u201362.","journal-title":"J Child Psychol Psychiatry"},{"key":"1227_CR3","doi-asserted-by":"publisher","first-page":"890","DOI":"10.15585\/mmwr.mm7340a1","volume":"73","author":"BS Staley","year":"2024","unstructured":"Staley BS, Robinson LR, Claussen AH, et al. Attention-deficit\/hyperactivity disorder diagnosis, treatment, and telehealth use in adults \u2014 National Center for Health Statistics Rapid Surveys System, United States, October\u2013November 2023. MMWR Morb Mortal Wkly Rep. 2024;73:890\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"11","key":"1227_CR4","doi-asserted-by":"publisher","first-page":"4823","DOI":"10.1038\/s41380-023-02228-3","volume":"28","author":"S Cortese","year":"2023","unstructured":"Cortese S, Song M, Farhat LC, et al. Incidence, prevalence, and global burden of ADHD from 1990 to 2019 across 204 countries: data, with critical re-analysis, from the global burden of disease study. Mol Psychiatry. 2023;28(11):4823\u201330.","journal-title":"Mol Psychiatry"},{"issue":"4","key":"1227_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2021.6401","volume":"176","author":"F Catala-Lopez","year":"2022","unstructured":"Catala-Lopez F, Hutton B, Page MJ, et al. Mortality in persons with autism spectrum disorder or attention-deficit\/hyperactivity disorder: a systematic review and meta-analysis. JAMA Pediatr. 2022;176(4):e216401.","journal-title":"JAMA Pediatr"},{"key":"1227_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s44192-022-00030-1","author":"BS da Silva","year":"2023","unstructured":"da Silva BS, Grevet EH, Silva LCF, et al. An overview on neurobiology and therapeutics of attention-deficit\/hyperactivity disorder. Discov Ment Health. 2023. https:\/\/doi.org\/10.1007\/s44192-022-00030-1.","journal-title":"Discov Ment Health"},{"key":"1227_CR7","unstructured":"Solomon MB, Yegla B, Newcorn J, et al. Revisiting the role of serotonin in attention deficit hyperactivity disorder [abstract no. S78 plus poster]. In: American Professional Society of ADHD and Related Disorders (APSARD) Annual Conference. 2024."},{"issue":"9","key":"1227_CR8","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","volume":"5","author":"S Cortese","year":"2018","unstructured":"Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727\u201338.","journal-title":"Lancet Psychiatry"},{"key":"1227_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.neubiorev.2018.02.001","volume":"87","author":"SV Faraone","year":"2018","unstructured":"Faraone SV. The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit\/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev. 2018;87:255\u201370.","journal-title":"Neurosci Biobehav Rev"},{"key":"1227_CR10","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-2528","author":"ML Wolraich","year":"2019","unstructured":"Wolraich ML, Hagan JF Jr., Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents. Pediatrics. 2019. https:\/\/doi.org\/10.1542\/peds.2019-2528.","journal-title":"Pediatrics"},{"issue":"3","key":"1227_CR11","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s13311-012-0130-0","volume":"9","author":"MA Stein","year":"2012","unstructured":"Stein MA, Weiss M, Hlavaty L. Adhd treatments, sleep, and sleep problems: complex associations. Neurotherapeutics. 2012;9(3):509\u201317.","journal-title":"Neurotherapeutics"},{"key":"1227_CR12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45995","author":"A Nanda","year":"2023","unstructured":"Nanda A, Janga LSN, Sambe HG, et al. Adverse effects of stimulant interventions for attention deficit hyperactivity disorder (ADHD): a comprehensive systematic review. Cureus. 2023. https:\/\/doi.org\/10.7759\/cureus.45995.","journal-title":"Cureus"},{"issue":"2","key":"1227_CR13","first-page":"157","volume":"110","author":"AE Olagunju","year":"2024","unstructured":"Olagunju AE, Ghoddusi F. Attention-deficit\/hyperactivity disorder in adults. Am Fam Physician. 2024;110(2):157\u201366.","journal-title":"Am Fam Physician"},{"key":"1227_CR14","unstructured":"U.S. Food and Drug Administration. FDA drug safety communication: FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions. 2023. https:\/\/www.fda.gov\/media\/168066\/. Accessed 2 Sep 2025."},{"issue":"6","key":"1227_CR15","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s40263-021-00825-w","volume":"35","author":"RL Findling","year":"2021","unstructured":"Findling RL, Candler SA, Nasser AF, et al. Viloxazine in the management of CNS disorders: a historical overview and current status. CNS Drugs. 2021;35(6):643\u201353.","journal-title":"CNS Drugs"},{"key":"1227_CR16","unstructured":"Supernus Pharmaceuticals Inc. QELBREE\u00ae (viloxazine extended-release capsules), for oral use: US prescribing information. 2025. https:\/\/www.accessdata.fda.gov\/. Accessed 2 Sep 2025."},{"key":"1227_CR17","unstructured":"U.S. Food and Drug Administration. QELBREE\u00ae (viloxazine) capsules: integrated review. 2021. https:\/\/www.accessdata.fda.gov\/. Accessed 2 Sep 2025."},{"key":"1227_CR18","unstructured":"Garcia-Olivares J, Yegla B, Earnest J, et al. Unraveling the mechanism of action of viloxazine ER in ADHD [abstract no. S67 plus poster]. In: American Professional Society of ADHD and Related Disorders (ASPARD) Annual Conference. 2024."},{"key":"1227_CR19","unstructured":"Earnest J, Garcia-Olivares J, Yegla B, et al. Characterization of viloxazine\u2019s serotonergic effects at doses relevant for ADHD treatment [abstract no. S40]. In: American Professional Society of ADHD and Related Disorders (ASPARD) Annual Conference. 2023."},{"key":"1227_CR20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2147\/JEP.S256586","volume":"12","author":"C Yu","year":"2020","unstructured":"Yu C, Garcia-Olivares J, Candler S, et al. New insights into the mechanism of action of viloxazine: serotonin and norepinephrine modulating properties. J Exp Pharmacol. 2020;12:285\u2013300.","journal-title":"J Exp Pharmacol"},{"key":"1227_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/JEP.S433524","volume":"16","author":"J Garcia-Olivares","year":"2024","unstructured":"Garcia-Olivares J, Yegla B, Bymaster FP, et al. Viloxazine increases extracellular concentrations of norepinephrine, dopamine, and serotonin in the rat prefrontal cortex at doses relevant for the treatment of attention-deficit\/hyperactivity disorder. J Exp Pharmacol. 2024;16:13\u201324.","journal-title":"J Exp Pharmacol"},{"issue":"5","key":"1227_CR22","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s00213-018-4872-1","volume":"235","author":"M Tiger","year":"2018","unstructured":"Tiger M, Varnas K, Okubo Y, et al. The 5-HT1B receptor - a potential target for antidepressant treatment. Psychopharmacology. 2018;235(5):1317\u201334.","journal-title":"Psychopharmacology"},{"issue":"6","key":"1227_CR23","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.4088\/JCP.20m13395","volume":"81","author":"A Nasser","year":"2020","unstructured":"Nasser A, Faison SL, Liranso T, et al. Evaluation of the effect of SPN-812 (viloxazine extended-release) on QTc interval in healthy adults. J Clin Psychiatry. 2020;81(6):e1\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"1227_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s13318-021-00729-6","volume":"47","author":"Z Wang","year":"2022","unstructured":"Wang Z, Kosheleff AR, Adeojo LW, et al. Impact of a high-fat meal and sprinkled administration on the bioavailability and pharmacokinetics of viloxazine extended-release capsules (QelbreeTM) in healthy adult subjects. Eur J Drug Metab Pharmacokinet. 2022;47(1):69\u201379.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"11","key":"1227_CR25","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1080\/00498254.2020.1767319","volume":"50","author":"C Yu","year":"2020","unstructured":"Yu C. Metabolism and in vitro drug-drug interaction assessment of viloxazine. Xenobiotica. 2020;50(11):1285\u2013300.","journal-title":"Xenobiotica"},{"issue":"5","key":"1227_CR26","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40261-024-01356-0","volume":"44","author":"Z Wang","year":"2024","unstructured":"Wang Z, Liranso T, Maldonado-Cruz Z, et al. Impact of viloxazine extended-release capsules (Qelbree\u00ae) on select cytochrome P450 enzyme activity and evaluation of CYP2D6 genetic polymorphisms on viloxazine pharmacokinetics. Clin Drug Investig. 2024;44(5):303\u201317.","journal-title":"Clin Drug Investig"},{"key":"1227_CR27","unstructured":"Wang Z, Lujan B, Adeojo LW, et al. Effect of hepatic impairment on the pharmacokinetics of a single-dose of viloxazine extended-release capsules (Qelbree\u00ae) in adults [poster]. In: 27th National Psychopharmacology UpdateTM, Nevada Psychiatric Association. 2022."},{"issue":"2","key":"1227_CR28","first-page":"126","volume":"14","author":"Y Cai","year":"2024","unstructured":"Cai Y, Wang Z, Alleyne N, et al. Pharmacokinetics of viloxazine extended-release capsules in breast milk of healthy lactating women [abstract plus poster 74]. Ment Health Clin [Internet]. 2024;14(2):126\u20137.","journal-title":"Ment Health Clin [Internet]."},{"issue":"2","key":"1227_CR29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40261-020-00992-6","volume":"41","author":"SL Faison","year":"2021","unstructured":"Faison SL, Fry N, Adewole T, et al. Pharmacokinetics of coadministered viloxazine extended-release (SPN-812) and methylphenidate in healthy adults. Clin Drug Investig. 2021;41(2):149\u201359.","journal-title":"Clin Drug Investig"},{"issue":"2","key":"1227_CR30","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/JCP.0000000000001361","volume":"41","author":"SL Faison","year":"2021","unstructured":"Faison SL, Fry N, Adewole T, et al. Pharmacokinetics of coadministered viloxazine extended-release (SPN-812) and lisdexamfetamine in healthy adults. J Clin Psychopharmacol. 2021;41(2):155\u201362.","journal-title":"J Clin Psychopharmacol"},{"issue":"11","key":"1227_CR31","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/cpdd.948","volume":"10","author":"Z Wang","year":"2021","unstructured":"Wang Z, Kosheleff AR, Adeojo LW, et al. Impact of paroxetine, a strong CYP2D6 inhibitor, on SPN-812 (viloxazine extended-release) pharmacokinetics in healthy adults. Clin Pharmacol Drug Dev. 2021;10(11):1365\u201374.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"8","key":"1227_CR32","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s40263-022-00938-w","volume":"36","author":"A Nasser","year":"2022","unstructured":"Nasser A, Hull JT, Chaturvedi SA, et al. A phase III, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of viloxazine extended-release capsules in adults with attention-deficit\/hyperactivity disorder. CNS Drugs. 2022;36(8):897\u2013915.","journal-title":"CNS Drugs"},{"issue":"11","key":"1227_CR33","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40263-024-01120-0","volume":"38","author":"A Childress","year":"2024","unstructured":"Childress A, Cutler AJ, Adler LA, et al. An open-label extension study assessing the long-term safety and efficacy of viloxazine extended-release capsules in adults with attention-deficit\/hyperactivity disorder. CNS Drugs. 2024;38(11):891\u2013907.","journal-title":"CNS Drugs"},{"key":"1227_CR34","unstructured":"Roth R, Isquith P, Teter C, et al. Qelbree\u00ae (viloxazine extended-release capsules) meaningfully improved executive function in adult ADHD: post-hoc analyses of phase III double-blind and open-label extension trials [abstract]. In: American Professional Society of ADHD and Related Disorders (APSARD) Annual Conference. 2025."},{"key":"1227_CR35","unstructured":"Childress A, Mattingly G, Cox G, et al. Treatment of ADHD in women: post hoc analysis of viloxazine ER (Qelbree\u00ae) safety and efficacy data stratified by sex [abstract]. In: 20th Annual Neuroscience Education Institute (NEI) Congress. 2024."},{"key":"1227_CR36","unstructured":"Cutler AJ, Childress A, Formella A, et al. Qelbree\u00ae (viloxazine ER) efficacy in adults with ADHD inattentive or combined presentations [abstract no. S10]. In: American Professional Society of ADHD and Related Disorders (ASPARD) Annual Conference. 2023."},{"key":"1227_CR37","doi-asserted-by":"crossref","unstructured":"Mattingly G, Young J, Earnest J, et al. Efficacy of viloxazine ER (Qelbree\u00ae) for ADHD in adults based on prior stimulant exposure [abstract no. T76 plus poster]. In: American Society of Clinical Psychopharmacology (ASCP) Annual Meeting. 2023.","DOI":"10.1017\/S1092852924001469"},{"key":"1227_CR38","unstructured":"Faraone S, Adler L, Roth R, et al. Impact of Qelbree\u00ae (viloxazine extended-release capsules) on self-rated executive function in a long-term, phase 3, open-label extension trial of adult ADHD [abstract no. S21 plus poster]. In: American Professional Society of ADHD and Related Disorders (ASPARD) Annual Conference. 2024."},{"key":"1227_CR39","unstructured":"Cutler A, Maletic V, Qin P, et al. Weight loss was more common than weight gain in adults treated with Viloxazine ER (Qelbree\u00ae) for ADHD in short and long-term phase 3 clinical trials [abstract]. In: 20th Annual Neuroscience Education Institute (NEI) Congress. 2024."},{"key":"1227_CR40","doi-asserted-by":"publisher","first-page":"1066988","DOI":"10.3389\/fphar.2022.1066988","volume":"13","author":"VA Nazarova","year":"2022","unstructured":"Nazarova VA, Sokolov AV, Chubarev VN, et al. Treatment of ADHD: drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials. Front Pharmacol. 2022;13:1066988.","journal-title":"Front Pharmacol"},{"key":"1227_CR41","unstructured":"American Professional Society of ADHD and Related Disorders. Guidelines for Adults with ADHD. 2025. https:\/\/apsard.org\/us-guidelines-for-adults-with-adhd\/. Accessed 2 Sep 2025."},{"key":"1227_CR42","unstructured":"Eli Lilly and Company. STRATTERA\u00ae (atomoxetine) capsules, for oral use: US prescribing information. 2022. https:\/\/www.accessdata.fda.gov\/. Accessed 2 Sep 2025."},{"issue":"6","key":"1227_CR43","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2165\/00128072-200305060-00005","volume":"5","author":"D Simpson","year":"2003","unstructured":"Simpson D, Perry CM. Atomoxetine. Paediatr Drugs. 2003;5(6):407\u201315.","journal-title":"Paediatr Drugs"},{"key":"1227_CR44","unstructured":"American Academy of Family Physicians. Treatment and management of ADHD in adults. 2025. https:\/\/www.aafp.org\/. Accessed 2 Sep 2025."},{"issue":"4","key":"1227_CR45","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/JCP.0000000000001404","volume":"41","author":"A Nasser","year":"2021","unstructured":"Nasser A, Liranso T, Adewole T, et al. A phase 3, placebo-controlled trial of once-daily viloxazine extended-release capsules in adolescents with attention-deficit\/hyperactivity disorder. J Clin Psychopharmacol. 2021;41(4):370\u201380.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"1227_CR46","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.clinthera.2021.01.027","volume":"43","author":"A Nasser","year":"2021","unstructured":"Nasser A, Liranso T, Adewole T, et al. Once-daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: a phase III randomized, controlled trial. Clin Ther. 2021;43(4):684\u2013700.","journal-title":"Clin Ther"},{"issue":"8","key":"1227_CR47","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.clinthera.2020.05.021","volume":"42","author":"A Nasser","year":"2020","unstructured":"Nasser A, Liranso T, Adewole T, et al. A phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit\/hyperactivity disorder in school-age children. Clin Ther. 2020;42(8):1452\u201366.","journal-title":"Clin Ther"},{"issue":"3","key":"1227_CR48","first-page":"309","volume":"107","author":"K Goodell","year":"2023","unstructured":"Goodell K, Erlich D. Viloxazine (Qelbree) for ADHD. Am Fam Physician. 2023;107(3):309\u201310.","journal-title":"Am Fam Physician"},{"issue":"11","key":"1227_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0277175","volume":"17","author":"WS Choi","year":"2022","unstructured":"Choi WS, Woo YS, Wang SM, et al. The prevalence of psychiatric comorbidities in adult ADHD compared with non-ADHD populations: a systematic literature review. PLoS ONE. 2022;17(11):e0277175.","journal-title":"PLoS ONE"},{"key":"1227_CR50","unstructured":"Chorniy A, Hurwitz JT, Grizzle A, et al. Differences in characteristics among children, adolescents, and adults with ADHD receiving viloxazine er, atomoxetine, or stimulants in open claims data [abstract]. In: American Professional Society of ADHD and Related Disorders (APSARD) Annual Conference. 2025."},{"key":"1227_CR51","unstructured":"Adler LA, Rose Lieberman V, Yarullina I, et al. Viloxazine ER for adults with attention-deficit\/hyperactivity disorder and mood symptoms: results of a decentralized, open-label, phase IV trial [abstract plus poster]. In: American Psychiatric Association Annual Meeting. 2025."},{"issue":"4","key":"1227_CR52","doi-asserted-by":"publisher","first-page":"705","DOI":"10.9758\/cpn.2021.19.4.705","volume":"19","author":"GH Bahn","year":"2021","unstructured":"Bahn GH, Seo K. Combined medication with stimulants and non-stimulants for attention-deficit\/hyperactivity disorder. Clin Psychopharmacol Neurosci. 2021;19(4):705\u201311.","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"5","key":"1227_CR53","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s40263-023-01005-8","volume":"37","author":"NV Radonji\u0107","year":"2023","unstructured":"Radonji\u0107 NV, Bellato A, Khoury NM, et al. Nonstimulant medications for attention-deficit\/hyperactivity disorder (ADHD) in adults: systematic review and meta-analysis. CNS Drugs. 2023;37(5):381\u201397.","journal-title":"CNS Drugs"},{"issue":"7","key":"1227_CR54","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s40263-023-01023-6","volume":"37","author":"MZ Price","year":"2023","unstructured":"Price MZ, Price RL. Extended-release viloxazine compared with atomoxetine for attention deficit hyperactivity disorder. CNS Drugs. 2023;37(7):655\u201360.","journal-title":"CNS Drugs"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01227-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01227-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01227-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:06:08Z","timestamp":1762884368000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01227-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":54,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1227"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01227-y","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yahiya Y. Syed is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}